TITLE:
Efficacy and Safety of Iron Isomaltoside Compared with an Oral Iron Supplement in the Management of Patients with Iron Deficiency Anemia
AUTHORS:
Zhimin Wu, Chunxiao Zhou, Chunyan Wu, Qiao Song, Shilyu Chen, Wen Zhang, Shaoling Wu
KEYWORDS:
Anemia, Iron-Deficiency, Drug Therapy, Iron Isomaltoside 1000, Treatment Outcome
JOURNAL NAME:
Open Journal of Blood Diseases,
Vol.14 No.1,
March
19,
2024
ABSTRACT: Objective: To evaluate the treatment outcome of iron isomaltoside compared with an
oral iron supplement in the management of iron deficiency anemia (IDA). Methods: The study included patients with IDA who visited the Outpatient Clinic of the
Department of Hematology, the Affiliated
Hospital of Qingdao University from October 2021 to August 2022 and met the
inclusion and exclusion criteria. According to the actual application of iron
supplementation, the patients were divided into two groups: iron isomaltoside treatment
group and oral iron treatment group.
Baseline measurements were collected before the start of treatment, and
measurements were collected subsequently at intervals of 1 week, 1 month, and 3
months. The hematological parameters analyzed included
Hemoglobin (Hb), Mean corpuscular hemoglobin (MCH), Mean Hemoglobin content
(MCH), Mean corpuscular Hemoglobin concentration (MCHC), and
Platelet (Plt). Safety data and adverse event profiles were recorded. Results: Intra-group comparisons: After 1 month of treatment, the Hb significantly
improved (P 0.05).
Inter-group comparisons: The biochemical parameters were significantly improved
(P 0.05) in the iron
isomaltoside group compared with those in the oral iron group after 1 month of
iron supplementation in patients with mild and moderate anemia. Adverse
reactions were tolerable for the patients in both iron isomaltoside group and
oral iron group. Only 1 patient in iron isomaltoside group developed
anaphylactic shock during medication and recovered after aggressive rescue. Conclusions: Iron isomaltoside which increases Hb more rapidly compared with the oral iron supplementation has few adverse reactions and
good acceptance.